SLC5A2 and Hyponatremia: It is noteworthy that the combined use of an SGLT-2 inhibitor and spironolactone did not impact the patient’s potassium levels adversely; however, we observed a trend of mild hyponatremia, with sodium levels ranging from 129–136 mmol/L, while urinary sodium remained normal.